Brachytherapy preserved erectile function in half of patients with prostate cancer

  • April 23, 2014

Permanent brachytherapy appears to maintain erectile function in 50% of patients with localized prostate cancer at 2 and 5 years after treatment, according to findings presented at the Congress of the European Society of Radiotherapy and Oncology.

In the prospective study, researchers assessed 285 patients, with a median age of 67.4 years, who underwent permanent prostate interstitial brachytherapy between July 1999 and October 2013. All eligible patients were required to have a minimum follow-up of 2 years and not be on an androgen deprivation therapy regimen. The median age of the study participants was 67.4 years.

Full Story »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

More»
More»
More»
  • Health Care Update
  • ARNOLD AND PORTER SILO
  • Medicare lab payments
  • New law will modernize Medicare lab payments: What physicians need to know. Analysis from Arnold & Porter LLP.
More »
  • Financial Planning
  • RUDZINSKI COLUMN
  • Advice for physicians
  • Be aware of important 2014 IRA updates. Analysis by Certified Financial Planner Ken Rudzinski.
More »
HemOnc Today